Neoprobe Corporation (OTC BB: NEOP) has focused their efforts on developing and commercializing novel biomedical products that address the critical intraoperative, diagnostic and therapeutic treatment needs of patients and physicians. The company’s main area of dedication is on improving cancer surgery outcomes by utilizing their market-leading gamma detection devices in conjunction with radiopharmaceutical agents.
- 17 years ago
QualityStocks
Neoprobe Corporation (OTC BB: NGNM)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Reports Q3 2025 Net Income of $1.5 Million and 42% Gross Margin, Highlighting Strong Operational Turnaround
Massimo Group (NASDAQ: MAMO), a provider of powersports vehicles and related equipment, reported revenue of…
-
QualityStocksNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Completes Montauban Mill Building, Moves Toward Commissioning and First Gold-Silver Production in 2026
This article has been disseminated on behalf of ESGold Corp. and may include paid advertising. ESGold…
-
QualityStocksNewsBreaks – D-Wave (NYSE: QBTS) Advantage2TM Quantum Computer Now Available for U.S. Government Applications at Davidson Technologies
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a global leader in quantum computing systems, software and…